American Diabetes Association 2013

American Diabetes Association 2013 | ADA 2013

At ADA 2013, more than 14,000 "top scientists, physicians and other health care professionals from around the world" will gather to "share cutting-edge research, treatment recommendations and advances toward a cure for diabetes."

Conference Coverages

Adopting a Centralized Glucose Management Program Improves Clinical Outcomes in General Hospital Patients with Diabetes
Adopting a Centralized Glucose Management Program Improves Clinical Outcomes in General Hospital Patients with Diabetes
By adopting a comprehensive set of case management policies for the care of diabetic and hyperglycemic patients, Johns Hopkins Hospital improved in-hospital mortality rate, reduced length of stay, and reduced hyperglycemia.
Study Indicates That Anti-Diabetic Therapies Do Not Increase Cancer Risk
Exposure to insulin glargine and metformin did not cause increased risk of cancer or worse cancer outcomes.
Experimental GLP-1 Receptor Agonist Associated with Better Glucose Control and Weight Effects than Sitagliptin and Glimepiride
Results of a three-year trial of the experimental GLP-1 receptor agonist albiglutide showed that it had a better effect on HbA1c, fasting blood glucose, and body weight than two comparator drugs.
Vitamin D, Pain, Depression, and Blood Pressure in Diabetic Women
Prescription-strength doses of vitamin D improve highly prevalent comorbidities among diabetic women, such as depression and pain, and also improve risk factors such as excess weight and high blood pressure.
Extreme Glycemic Control Not Significantly Associated with Increased All-Cause Mortality
While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.
Study Shows Benefits of Adopting Novel Insulin Dose Adjustment Algorithm
A novel algorithm for patient self-adjustment of prandial insulin dose could make it easier for patients who are poorly-controlled on basal insulin to add meal-time insulin.
Treatment with Exenatide Plus Insulin Glargine Associated with Decrease in Fasting Glucose and Body Weight
In patients with type 2 diabetes currently taking metformin, treatment with combination exenatide plus insulin glargine decreased fasting glucose and resulted in greater weight loss compared to treatment with insulin lispro plus insulin glargine.
Experimental Dulaglutide Is Superior to Sitagliptin in One-Year Trial
Study shows dulaglutide improved glycemic control in patients at 52 weeks compared to sitagliptin, but with a higher rate of adverse events.
Combination Liraglutide and Insulin Degludec Is Safe and Effective in Type 2 Diabetes
Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.

Most Popular


$vacMongoViewPlus$ $vAR$